t: +44 (0)115 784 0041
Co-founder of Locate alongside Professor Shakesheff. A registered pharmacist and pharmaceutical industry trained. Rob has a PhD in biomaterials research and has worked for the past 15 years within the field of regenerative medicine, the past 12 as an Executive Company Director. Recently completed an Executive MBA in Healthcare at the University of Nottingham Business School and was awarded “Best Overall Performance on the Executive MBA (2014/15)”.
An internationally-respected key opinion leader in drug development and a serial entrepreneur, his background includes strong scientific, business, managerial and deal-making experience. Ian has previously founded, managed and developed a number of successful bioscience start-up companies, including Pharmaceutical Profiles Ltd. (recipient of a Frost & Sullivan Excellence in Technology Award) which, as Chief Executive, he grew to over 110 employees and a 10 Million GBP turnover. He presently sits on the board of Zysis, with previous board positions including Bend Research, Modern Biosciences and R5 Pharmaceuticals.
Following his return from the Langer Laboratories at M.I.T, Kevin has taken a leading role in shaping cell therapy and tissue engineering in the UK as a co-founder of the Tissue and Cell Engineering Society (now 12 years old), as a Co-Director of the EPSRC Centre for Innovative Manufacturing in Regenerative Medicine and as a member of the Biologics and Vaccinces Expert Advisory Group of the MHRA. In 2013 he was appointed Director of the UK Regenerative Medicine Platform Hub in Acellular Technologies. Kevin has published over 220 peer-reviewed full papers (10,000 citations to date) and his work has generated 13 patent application families and numerous international awards.
Andrew has been with Heraeus since 2006 and has had a number of roles in the company, including Head of Product Management. Prior to this, he was in private practice and worked for a SE Asian healthcare provider. He holds a postgraduate qualification in Corporate Finance and International Management (LSBF, Judge and St Gallen).
Catherine is medically qualified and has held several senior management roles in the pharmaceutical industry in the UK and abroad. She was founder of the Cambridge Gateway Fund, a Venture Capital fund focused on technology investments, which she sold in 2007. Catherine advises the UK Government on investment strategy and is on the board of several healthcare companies. Until very recently was the CEO of Oval Medical Limited, a leading developer of innovative and novel drug delivery devices. Catherine was awarded the Order of the British Empire (OBE) in the Queen’s Birthday Honours in June 2008 for her services to innovation and technology.